BIO-Europe Spring Interviews
Former EMA boss Lönngren proposes hard Brexit solution
Pharma is clearly worried about how the UK's exit from the EU will disrupt both the EMA's capacity for drugs reviews and the pan-European regulatory environment. Former EMA executive director Thomas Lönngren explained to Scrip during the BIO-Europe Spring meeting that the relationship between EMA and FDA could be a model the UK's MHRA could adopt if the British take a hard Brexit route.